Effects of ibopamine on systemic, pulmonary and regional hemodynamics. Experimental investigations in anesthetized dogs
- PMID: 3707641
Effects of ibopamine on systemic, pulmonary and regional hemodynamics. Experimental investigations in anesthetized dogs
Abstract
The effects of a new orally effective dopamine-like derivative, ibopamine (SB-7505), the 3,4-diisobutyryl ester of N-methyldopamine, on the cardiovascular system were investigated in anesthetized dogs. Ibopamine increased dose-dependently stroke volume index, cardiac index, left ventricular pressure, its first derivative: dP/dt, peak velocity left ventricular ejection and renal blood flow. After beta-blockade the positive inotropic effect of ibopamine is inhibited. Total peripheral resistance and renal vascular resistance decreased after ibopamine. Urine output was increased dose-dependently, reaching 115% after ibopamine 8 mg/kg intraduodenally. Coronary and femoral flows and resistance did not change after administration of 4 and 8 mg/kg. Only very high doses (24 mg/kg) caused an increase in flow and resistance. Mesenteric flow decreased transiently and then returned to the previous level or increased considerably over the basal figures when a high dose was used. No significant changes or fall in heart rate were observed with doses up to 16 mg/kg and no significant changes in pulmonary resistance were noted. The data obtained from the present investigation show, however, that oral ibopamine is capable of producing most of the effects induced by intravenously given dopamine in anesthetized dogs. Ibopamine's cardiac and renal effects may open new prospects for the long-term treatment of chronic heart failure in human subjects.
Similar articles
-
Systemic and coronary hemodynamic actions of the novel inotropic agent, ibopamine, and the de-esterified metabolite and active form, epinine: relationship to left ventricular performance in the dog.J Pharmacol Exp Ther. 1988 Aug;246(2):434-40. J Pharmacol Exp Ther. 1988. PMID: 3404441
-
Effects of ibopamine on peripheral hemodynamics: a strain gauge plethysmographic study in patients with congestive heart failure.Arzneimittelforschung. 1986 Feb;36(2A):380-2. Arzneimittelforschung. 1986. PMID: 3707654
-
Effects of ibopamine on acute cardiac failure following experimental coronary occlusion in dogs.Arzneimittelforschung. 1986 Feb;36(2A):331-3. Arzneimittelforschung. 1986. PMID: 3707644
-
[Ibopamine--clinical results].Z Kardiol. 1991;80 Suppl 8:71-6. Z Kardiol. 1991. PMID: 1686695 Review. German.
-
Cardiovascular and renal action of dopaminergic prodrugs.J Cardiovasc Pharmacol. 1989;14 Suppl 8:S40-59. J Cardiovasc Pharmacol. 1989. PMID: 2483441 Review.
Cited by
-
Ibopamine. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.Drugs. 1988 Jul;36(1):11-31. doi: 10.2165/00003495-198836010-00003. Drugs. 1988. PMID: 3063492 Review.
-
Peripheral hemodynamic effects of ibopamine in patients with congestive heart failure. A placebo-controlled, double-blind study.Cardiovasc Drugs Ther. 1989 Apr;3(2):199-202. doi: 10.1007/BF01883865. Cardiovasc Drugs Ther. 1989. PMID: 2487532 Clinical Trial.
-
Early cardiovascular changes with ibopamine: evidence for a biphasic haemodynamic action.Br J Clin Pharmacol. 1987 Oct;24(4):435-42. doi: 10.1111/j.1365-2125.1987.tb03195.x. Br J Clin Pharmacol. 1987. PMID: 3689625 Free PMC article.
-
Ibopamine-induced reduction of serum prolactin level and milk secretion in puerperal women.Eur J Clin Pharmacol. 1990;39(2):133-5. doi: 10.1007/BF00280046. Eur J Clin Pharmacol. 1990. PMID: 2253662 Clinical Trial.